Rigel Pharmaceuticals looks cheap for a reason, but it may still be too cheap. At roughly $32.08 per share and a $592.6 million market cap on June 12, 2026, the stock screens like a mistake: a reported trailing P/E of about 1.66, positive net income, and a commercial biotech business that just posted another profitable quarter. The catch is that the ultra-low multiple is flattered by a massive deferred tax benefit in 2025. This RIGL stock analysis comes down to one question: after you strip out the accounting noise, is the underlying business still cheap enough to own?
I think the answer is yes, with a big asterisk. Rigel now has a real commercial engine, not just a pipeline story. First-quarter 2026 revenue was $58.8 million, net product sales grew 26% year over year to $54.9 million, and management reaffirmed full-year 2026 revenue guidance of $275 million to $290 million. On top of that, Rigel signed a potentially transformative VEPPANU licensing deal in May. That is the good news. The bad news is that Rigel is also taking on launch risk, milestone obligations, and the market is no longer pricing this like a sleepy niche drug company.
RIGL is also a current name in Margin of Alpha’s paper portfolio, so this is a live thesis, not an academic exercise.
RIGL stock analysis starts with one fake number
If you look at the headline P/E and stop there, you will get the story wrong.
Rigel reported $367.0 million of net income for full-year 2025, but that figure included about $245.9 million of non-cash deferred income tax benefit. That matters because it makes the trailing earnings multiple look absurdly low. The market is not giving you a profitable commercial biotech at 1.6x normalized earnings. It is giving you a company whose reported earnings were temporarily juiced by an accounting event.
That said, the stock is not expensive even after you clean that up. The part I care about is that Rigel remained profitable in the first quarter of 2026 without any tax-benefit fireworks. Net income came in at $8.7 million, or $0.44 diluted EPS, on $58.8 million of revenue. Income before income taxes was $11.7 million. That tells me the core business is real enough to support the pipeline and at least some business-development ambition.
The balance sheet is also in decent shape for a small biotech trying to act bigger. As of March 31, 2026, Rigel had $146.7 million in cash, cash equivalents, and short-term investments, according to its Q1 2026 10-Q. The company also reworked its debt structure in early May, replacing its term loan with a revolving credit facility of up to $40 million, expandable to $60 million, and drawing $8 million at closing. That is not a fortress balance sheet, but it is far from the usual small-cap biotech desperation setup.
The commercial business is stronger than most people think
Rigel is no longer a one-drug bet. The commercial portfolio has three approved products generating real revenue.
In Q1 2026, TAVALISSE net product sales were $37.3 million, up 31% year over year. GAVRETO contributed $9.6 million, up 7%. REZLIDHIA added $8.0 million, up 31%. That mix matters. It means Rigel is not depending on one heroic launch to keep the lights on. It already has a base business with multiple growth levers.
Full-year guidance reinforces that point. Management reiterated 2026 total revenue guidance of $275 million to $290 million, including $255 million to $265 million of net product sales and $20 million to $25 million of contract revenue. For a company with a sub-$600 million market cap, that is enough scale to matter.
This is where Rigel starts to look more interesting than the average small-cap biotech pitch. Most tiny biotech names ask you to fund years of dilution in exchange for maybe one data readout. Rigel already has marketed assets, positive net income guidance, and cash generation history. That does not make it safe. It does make it easier to underwrite.
If you have been following some of our other live portfolio names, Rigel sits in a different bucket than earlier high-beta biotech trades like AGEN or speculative names like PROK. It is closer to the higher-quality commercial profile we liked in CPRX, even if the revenue base and risk profile are still messier.
The VEPPANU deal is why the RIGL story changed in May
The May 12 licensing agreement for VEPPANU is the reason this stock can re-rate from “cheap commercial biotech” into “something bigger.” Rigel agreed to acquire exclusive global rights to develop, manufacture, and commercialize VEPPANU from Arvinas and Pfizer, subject to closing conditions expected in mid-June 2026.
This is not some distant preclinical flyer. VEPPANU was approved by the FDA on May 1, 2026 for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least one line of endocrine therapy. In the Phase 3 VERITAC-2 trial, median progression-free survival was 5.0 months versus 2.1 months for fulvestrant, with a hazard ratio of 0.57 and a p-value of 0.0001. That is not hand-wavy “encouraging data.” That is commercially usable efficacy in a real oncology market.
The opportunity is obvious. Breast cancer is a much larger commercial market than Rigel’s current hematology and oncology niche products. If VEPPANU launches well, Rigel’s revenue base can step up in a way that the current valuation does not fully reflect.
The terms are also big enough to matter. Rigel is paying $70 million upfront, another $15 million after transition milestones, up to $40 million toward certain development activities over four years, and as much as $320 million in future regulatory and commercial milestones. Arvinas and Pfizer also keep tiered royalties in the mid-teens to mid-twenties.
That is exactly why the market is cautious. VEPPANU could become Rigel’s fourth commercial product and the company’s biggest growth driver. It could also become a capital sink if launch uptake disappoints, reimbursement is slower than expected, or the royalty-and-milestone stack soaks up the economics.
The bear case is not hard to find
The cleanest bear argument is that the stock is optically cheap but not truly cheap.
First, the reported P/E is distorted. Anyone buying RIGL because a screener says “1.6x earnings” is already behind. The more honest way to look at the company is as a profitable but still execution-heavy commercial biotech with one existing revenue base and one large acquired growth option layered on top.
Second, Rigel just lost one partnered asset while buying another. Eli Lilly notified Rigel in April that it will terminate the ocadusertib collaboration effective June 15, 2026. That is not catastrophic on its own, but it is a reminder that pipeline value can evaporate quickly and partners do not always stick around.
Third, VEPPANU raises the bar. Once a company buys a bigger future, it stops getting graded on simply being profitable. Investors will want evidence that Rigel can integrate the asset, execute the launch, manage the supply chain handoff, and still protect margins. If management misses on any of those, the multiple can compress even if revenue grows.
Fourth, small-cap biotech stocks still trade like small-cap biotech stocks. Even with three commercial products, Rigel is a sub-$600 million company with drug concentration risk, reimbursement risk, and pipeline risk. You are never far from a nasty drawdown in this part of the market.
What I would watch next
If you are doing real work on the name, four checkpoints matter more than day-to-day price action.
One, watch whether the VEPPANU transaction closes on schedule in mid-June 2026 and whether management gives more concrete launch expectations after closing.
Two, track the commercial trajectory of the existing portfolio. TAVALISSE, GAVRETO, and REZLIDHIA need to keep growing, because that base business is what funds the rest of the story.
Three, pay attention to the R289 lower-risk MDS program. Rigel says it is on track to complete enrollment in the dose expansion phase and select the recommended Phase 2 dose in the second half of 2026, with preliminary data expected by year-end. That can become the next sentiment driver if the commercial story pauses.
Four, watch how management talks about capital allocation after the VEPPANU close. A company can destroy a decent small-cap setup fast if it starts chasing every business-development opportunity just because one deal worked.
Verdict: compelling, but only if you price in the catch
My take is simple: RIGL is interesting here because the real business is stronger than the headline skeptics assume, but the fake-low P/E is weaker than the headline bulls assume.
At roughly $32, I think the stock is still compelling for investors who want a small-cap biotech with real revenue, current profitability, and a legitimate upside catalyst from VEPPANU. I would not frame it as a bargain-bin 1.6x earnings miracle. I would frame it as a company with a commercial floor and a much bigger oncology call option attached.
If the VEPPANU launch starts well and the legacy portfolio holds up, the stock can still work from here. If the launch stumbles, the market is going to remember very quickly that this is still a small biotech wearing a larger company’s clothes.
That is why I like it under $35 but would get less excited if the stock ran into the low $40s before investors see any real VEPPANU execution data.
Disclosure: Margin of Alpha currently tracks RIGL in its paper portfolio.
Financial Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always do your own research and consider consulting with a financial advisor before making investment decisions.